ESR1 and breast carcinoma: Approximately 75% of breast cancers are oestrogen receptor–positive (ER +) and 5–10 years of adjuvant endocrine therapy (ET) halves the risk of recurrence and reduces mortality by one-third in ER + women [2, 3].